Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results Record total revenue of $799 million, reflecting 12 percent growth over the second quarter of 2024 and 12 consecutive quarters of double-digit, year-over-year total revenue growth Share repurchase of up to$1 billion authorized by the Board of Directors, expiring March 31, 2026 Tyvaso DPI® record total revenue of $315 million, reflecting 22 percent growth over the second quarter of 2024; n ...